Effects of indoor air pollution on clinical outcomes in patients with interstitial lung disease: protocol of a multicentre prospective observational study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Hee-Young | - |
dc.contributor.author | Kim, Sun-Young | - |
dc.contributor.author | Song, Jin Woo | - |
dc.date.accessioned | 2024-06-11T07:32:27Z | - |
dc.date.available | 2024-06-11T07:32:27Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.issn | 2052-4439 | - |
dc.identifier.issn | 2052-4439 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26046 | - |
dc.description.abstract | BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrosing interstitial lung disease with a poor prognosis. While there is evidence suggesting that outdoor air pollution affects the clinical course of IPF, the impact of indoor air pollution on patients with IPF has not been extensively studied. Therefore, this prospective multicentre observational study aims to investigate the association between indoor air pollution and clinical outcomes in patients with IPF.Methods and analysisThis study enrolled 140 patients with IPF from 12 medical institutes in the Seoul and Metropolitan areas of the Republic of Korea. Over the course of 1 year, participants visited the institutes every 3 months, during which their clinical data and blood samples were collected. Additionally, indoor exposure to particulate matter <= 2.5 mu m (PM2.5) was measured using MicroPEM (RTI International, Research Triangle Park, North Carolina, USA) in each participant's house for 5 days every 3 months. Lung function was assessed using both site spirometry at each institution and portable spirometry at each participant's house every 3 months. The study will analyse the impact of indoor PM2.5 on clinical outcomes, including mortality, acute exacerbation, changes in lung function and health-related quality of life, in the participants. This study represents the first attempt to evaluate the influence of indoor air pollution on the prognosis of patients with IPF.Ethics and disseminationThis study has received approval from the institutional review board of all participating institutions, including Asan Medical Center, Seoul, Republic of Korea (2021-0072).Trial registration numberKCT0006217. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | Effects of indoor air pollution on clinical outcomes in patients with interstitial lung disease: protocol of a multicentre prospective observational study | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1136/bmjresp-2023-002053 | - |
dc.identifier.scopusid | 2-s2.0-85183458095 | - |
dc.identifier.wosid | 001148416900001 | - |
dc.identifier.bibliographicCitation | BMJ OPEN RESPIRATORY RESEARCH, v.11, no.1 | - |
dc.citation.title | BMJ OPEN RESPIRATORY RESEARCH | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | IDIOPATHIC PULMONARY-FIBROSIS | - |
dc.subject.keywordPlus | FORCED VITAL CAPACITY | - |
dc.subject.keywordPlus | ACUTE EXACERBATION | - |
dc.subject.keywordPlus | PM2.5 | - |
dc.subject.keywordPlus | STANDARDIZATION | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Interstitial Fibrosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.